{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:09:36Z","timestamp":1794665376625,"version":"4.9.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009448","name":"University of Campania Luigi Vanvitelli","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["metabolismjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.metabol.2021.154936","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T07:54:59Z","timestamp":1637222099000},"page":"154936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"special_numbering":"C","title":["Sodium\/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts"],"prefix":"10.1016","volume":"127","author":[{"given":"Raffaele","family":"Marfella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"D'Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Consiglia","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestino","family":"Sardu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Scisciola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Amarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Balestrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gelsomina","family":"Mansueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Golino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"De Feo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Maiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Paolisso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2021.154936_bb0005","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2021.154936_bb0010","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2021.154936_bb0015","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","article-title":"Glycemic control and heart failure among adult patients with diabetes","volume":"103","author":"Iribarren","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2021.154936_bb0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","article-title":"Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy","volume":"71","author":"Marwick","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2021.154936_bb0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ecl.2013.09.007","article-title":"The relationships between cardiovascular disease and diabetes: focus on pathogenesis","volume":"43","author":"Kovacic","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.metabol.2021.154936_bb0030","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/eurheartj\/ehy903","article-title":"Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy","volume":"40","author":"Costantino","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2021.154936_bb0035","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/CIRCRESAHA.120.317132","article-title":"Hyperglycemia induces myocardial dysfunction via epigenetic regulation of JunD","volume":"127","author":"Hussain","year":"2020","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.metabol.2021.154936_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells\u2014renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.metabol.2021.154936_bb0045","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1093\/ehjcvp\/pvab039","article-title":"SGLT2 inhibitors in cardiovascular medicine","volume":"7","author":"Varzideh","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.metabol.2021.154936_bb0050","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fendo.2020.00190","article-title":"Prospect of sodium-glucose co-transporter 2 inhibitors combined with insulin for the treatment of type 2 diabetes","volume":"11","author":"Yang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2021.154936_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.604250","article-title":"Sodium-glucose co-transporter 2 inhibitors reduce the risk of heart failure hospitalization in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.metabol.2021.154936_bb0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12933-020-01191-5","article-title":"How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition?","volume":"19","author":"Tanaka","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2021.154936_bb0065","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2020.01.018","article-title":"Lipid accumulation in hearts transplanted from nondiabetic donors to diabetic recipients","volume":"75","author":"Marfella","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"10.1016\/j.metabol.2021.154936_bb0070","first-page":"67","volume":"2016","author":"Gali\u00e8","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2021.154936_bb0075","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/ehjci\/jev139","article-title":"Document reviewers. European Association of Cardiovascular Imaging\/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation","volume":"16","author":"Badano","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.metabol.2021.154936_bb0080","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","volume":"18","author":"Galderisi","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.metabol.2021.154936_bb0085","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00125-012-2749-0","article-title":"Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation","volume":"56","author":"Balestrieri","year":"2013","journal-title":"Diabetologia."},{"key":"10.1016\/j.metabol.2021.154936_bb0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.freeradbiomed.2016.04.013","article-title":"Ergothioneine oxidation in the protection against high-glucose induced endothelial senescence: involvement of SIRT1 and SIRT6","volume":"96","author":"D\u2019Onofrio","year":"2016","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10.1016\/j.metabol.2021.154936_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction","volume":"11","author":"Komiya","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2021.154936_bb0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41581-020-00391-2","article-title":"SGLT2 inhibitors may offer benefit beyond diabetes","volume":"17","author":"Kang","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.metabol.2021.154936_bb0105","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018889","article-title":"Neurohormonal activation and heart failure development","volume":"9","author":"Gronda","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2021.154936_bb0110","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-021-10096-8","article-title":"SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism","author":"Wang","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.metabol.2021.154936_bb0115","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.metabol.2021.154936_bb0120","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.metabol.2021.154936_bb0125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.metabol.2004.08.014","article-title":"Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea","volume":"54","author":"Kang","year":"2005","journal-title":"Metabolism."},{"key":"10.1016\/j.metabol.2021.154936_bb0130","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc12-0840","article-title":"Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans","volume":"36","author":"Pisprasert","year":"2013","journal-title":"Diabetes Care"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521002365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049521002365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T23:57:58Z","timestamp":1642550278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049521002365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":26,"alternative-id":["S0026049521002365"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154936","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium\/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154936","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"154936"}}